NCT07042490Not yet recruiting
Efficacy and Safety of Plasma Adsorption Combined With EVT for AIS-LVO
Efficacy and Safety of Plasma Adsorption Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation: A Multicenter, Randomized, Parallel-controlled Clinical Trial
Source: ClinicalTrials.gov · Last updated 29 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to determine the efficacy and safety of plasma adsorption for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 17 Jun 2025
- Start date
- 30 Jun 2025
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Yi Yang
- Diseases
- Stroke
- NCT number
- NCT07042490
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 30 Jun 2025 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of organic heart disease and NYHA Class III or IV.
- Current or past participation in other clinical research, or participation in this study within 3 months prior to admission.
Other illness
- Imaging after EVT indicated malignant brain edema with midline shift or brain herniation and surgical treatment was planned.
- Parenchymal hemorrhage type 1, or type 2 confirmed by CT.
- Allergic to any ingredient of the plasma separator, the adsorption device, or the piping.
- Previous history of malignant tumors, autoimmune diseases or being treated with immunosuppressants, hormones, or tumor necrosis factor inhibitors.
- Other conditions that the researchers think make the patient unsuitable for the study.
Lab values
- Contraindications to plasma adsorption, platelet count \<60×10\^9/L,white blood cell\<4×10\^9/L, uncontrolled hypertension with persistent systolic blood pressure ≥200 mmHg or diastolic blood pressure ≥110 mmHg, uncontrolled hypotension, systolic blood pressure \<90 mmHg or diastolic blood pressure \<60 mmHg.
- Currently taking anticoagulant(dabigatran, rivaroxiban, warfarin, etc.), previous history of serious hematological system disorders, or abnormal coagulation function (international normalized ratio \[INR\], activated partial thromboplastin time \[APTT\], prothrombin time \[PT\] upper limit of the normal range).
- Severe liver and kidney dysfunction or abnormal laboratory test results(serum aspartate aminotransferase or alanine aminotransferase \>3 times the upper limit of normal, serum creatinine\>265umol/l(\>3mg/dl)).
Other
- Pregnancy , lactation or life expectancy of less than 3 months or inability to complete the study for other reasons.
- Unwilling to be followed up or poor compliance.
Who the study is looking for
- Age 18-80 years, male or female.
- Diagnosis of acute ischemic stroke within 12 hours of symptom onset, underwent endovascular thrombectomy (EVT) adhering to current guidelines for large vessel occlusion in the anterior circulation (confirmed by DSA as ICA,MCA-M1,MCA-M2,ACA-A1,ACA-A2 occlusion or tandem lesion) and achieve successful recanalization (mTICI grade 2b/3).
- Baseline NIHSS after EVT ≥ 6 and ≤25 points.
- Randomization and the first plasma adsorption can be initiated within 12 hours after EVT.
- Pre-stroke mRS≤ 2 points.
- Patient/legally family members have signed the Informed consent form.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Hospital of Jilin University Coordinator of this site? Confirm its status | Changchun | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.